Democrats Are Lying Again
The Dems' Main Narrative for the Schumer Shutdown Is Falling Apart
CNN's Van Jones Reveals What Schumer Told Him Three Months Ago About Shutting...
AG Bondi to Appeal 'Woefully Insufficient' Sentence for Justice Kavanaugh's Would-be Assas...
No, NYT, We Don't Need to Feel Bad for These People
Scott Wiener: Accusations of Fascism Will Continue Until Conservatives Bend the Knee to...
Colorado Authorities Reopen Investigation Into Death of Hunter S. Thompson
Has Anyone Asked the Archbishop If She Believes in God?
Dirty Hospitals Are to Blame for Superbug Deaths
Hope Amid Chaos in Nigeria
The Train of Progress Must Not Be Derailed
Trump Ends the Green Scam — Now the Crying Caucus Is Out of...
Make Protecting Animals Great Again: The Trump Administration Is Ending Animal Cruelty
Hochu v. Mamdani: The Upcoming War Over NYC Tax Increases
More Government Control Over College Sports Is the Wrong Fix
Tipsheet

The FDA Just Approved This Surprising Standalone Treatment for Depression

AP Photo/Andrew Harnik, File

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray to be used alone in adults with major depressive disorder. 

Advertisement

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression. This is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.

According to CNBC, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing thoughts of suicide or harm. 

“We want to recognize that this is a medicine that treats a disease that [when] left untreated, depression is potentially fatal,” Bill Martin, J&J’s global therapeutic area head of neuroscience, said in an interview with the outlet.

Advertisement

Reportedly, about one-third of the estimated 21 million U.S. adults with major depression battle symptoms don’t respond to treatment.

“For the first time ever, we now have an option that gives patients freedom,” Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said. 

Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren’t improving their symptoms and are causing undesirable side effects.

The approval of Spravato was based on a phase four trial that showed that Spravato alone improved depressive symptoms beginning about 24 hours after treatment and lasting through at least one month. The drug first entered the US market in 2019.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement